Polymeric solid supports designed for precision, scalability, and consistent performance in therapeutic oligonucleotide development.
Since 2004, Kinovate has been a market leader in high-performance polymeric solid supports, offering flexible loading ranges, custom chemistries, and ISO 9001:2015-compliant manufacturing for clinical and commercial programs.
Available loading ranges from 40 to >400 µmol/g
Kinovate’s polymeric solid supports are engineered to deliver consistency, scalability, and performance at every stage of therapeutic development.
NittoPhase™ platforms provide high-performance polymeric solid supports designed for reliable synthesis, flexible loading ranges, and consistent results across clinical and commercial scales.
The oligonucleotide therapeutics field is evolving toward improved process economy and manufacturing productivity, driving increased interest in convergent and fragment-based assembly strategies. These emerging approaches rely on efficient, scalable production of short-mer oligonucleotide building blocks rather than high-loading full-length synthesis. NittoPhase™ SL is a next-generation solid support engineered with elevated functional density to address this need.
Up to 650 µmol/g linker loading density achieved
*Linker dependent, though 600+ expectedly achievable
Kinovate Life Sciences is a wholly owned subsidiary of Nitto Denko Corporation, established in 2004 to deliver high-quality polymeric materials for therapeutic oligonucleotide synthesis.
Backed by deep polymer science expertise and ISO 9001:2015-compliant manufacturing, Kinovate is trusted worldwide for performance, reliability, and secure supply across clinical and commercial programs.
